Organogenesis Holdings Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
(amounts in thousands, except share amounts)
| Additional | |||||||
|---|---|---|---|---|---|---|---|
| Redeemable Convertible Preferred Stock · Common Stock · Paid-in · Accumulated · Total | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Stockholders’ Equity | |
| Balance as of December 31, 2025 | 130,000 | $133,789 | 126,951,876 | $13 | $303,194 | $(3,078) | $300,129 |
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | — | 3,003 | — | — | (3,003) | — | (3,003) |
| Vesting of RSUs and PSUs, net of shares surrendered to pay taxes | — | — | 1,722,672 | — | (3,051) | — | (3,051) |
| Stock-based compensation expense | — | — | — | — | 3,636 | — | 3,636 |
| Net loss | — | — | — | — | — | (53,156) | (53,156) |
| Balance as of March 31, 2026 | 130,000 | $136,792 | 128,674,548 | $13 | $300,776 | $(56,234) | $244,555 |
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | — | 3,072 | — | — | (3,072) | — | (3,072) |
| Stock-based compensation expense | — | — | — | — | 3,052 | — | 3,052 |
| Net loss | — | — | — | — | — | (96,267) | (96,267) |
| Balance as of June 30, 2026 | 130,000 | $139,864 | 128,674,548 | $13 | $300,756 | $(152,501) | $148,268 |
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (Continued)
(amounts in thousands, except share amounts)
| Additional | |||||||
|---|---|---|---|---|---|---|---|
| Redeemable Convertible Preferred Stock · Common Stock · Paid-in · Accumulated · Total | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Stockholders’ Equity | |
| Balance as of December 31, 2024 | 130,000 | $122,419 | 125,730,236 | $13 | $302,994 | $(40,110) | $262,897 |
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | — | 2,748 | — | — | (2,748) | — | (2,748) |
| Exercise of stock options | — | — | 20,016 | — | 25 | — | 25 |
| Vesting of RSUs, net of shares surrendered to pay taxes | — | — | 1,103,284 | — | (1,796) | — | (1,796) |
| Stock-based compensation expense | — | — | — | — | 3,367 | — | 3,367 |
| Net loss | — | — | — | — | — | (18,843) | (18,843) |
| Balance as of March 31, 2025 | 130,000 | $125,167 | 126,853,536 | $13 | $301,842 | $(58,953) | $242,902 |
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | — | 2,810 | — | — | (2,810) | — | (2,810) |
| Stock-based compensation expense | — | — | — | — | 2,542 | — | 2,542 |
| Net loss | — | — | — | — | — | (9,392) | (9,392) |
| Balance as of June 30, 2025 | 130,000 | $127,977 | 126,853,536 | $13 | $301,574 | $(68,345) | $233,242 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.